InfuSystem director awarded 24,890 stock options
InfuSystem Holdings director Paul Andrew Gendron received a new stock option grant as part of his compensation.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
InfuSystem Holdings director Paul Andrew Gendron received a new stock option grant as part of his compensation. He was granted options to acquire 24,890 shares of common stock at an exercise price of $8.37 per share, expiring in 2036. These options vest on May 12, 2027. Following the reported transactions, he directly holds 70,000 shares of InfuSystem common stock, indicating this filing reflects equity-based incentives rather than open-market buying or selling.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (right to buy) | 24,890 | $0.00 | $0.00 |
| Holding | Common Stock | -- | -- | -- |
Footnotes (1)
- F1. The option, representing the right to purchase 24,890 shares of InfuSystem Holdings, Inc. common stock, vests on May 12, 2027.
Key Figures
Key Terms
Stock Option (right to buy) financial
Grant, award, or other acquisition financial
exercise price financial
vests financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did InfuSystem (INFU) report for Paul Andrew Gendron?
What are the key terms of Paul Andrew Gendron’s new InfuSystem (INFU) stock options?
When do Paul Andrew Gendron’s InfuSystem (INFU) stock options vest and expire?
AI-generated analysis. How Rhea-AI works. Not financial advice.